Cargando…
Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
Despite the significant clinical benefits, checkpoint inhibition is associated with a unique spectrum of immune-related adverse events. It is sometimes difficult to distinguish some rare adverse effects from a cancer progression; thus, such effects should be reported in clinical trials to be diagnos...
Autores principales: | Tsukamoto, Jessica, Monteiro, Mariana, Vale, Silvana, Lemos, Cynthia, Scarpelli, Thais, Carvalho, Leticia, Pezzutti, Daniela, Brandão, Raphael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243904/ https://www.ncbi.nlm.nih.gov/pubmed/30483092 http://dx.doi.org/10.1159/000492463 |
Ejemplares similares
-
Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments
por: Armentano, Daniela Pezzutti Domigues, et al.
Publicado: (2022) -
Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study
por: Zhu, Jie, et al.
Publicado: (2023) -
Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
por: Alghamdi, Eman A., et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021) -
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)